Article
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy.
European journal of cancer (Oxford, England : 1990) - 3 Jun 2026
Arriola Edurne, Casarini Ignacio, Özgüroğlu Mustafa, Huang Meijuan, Takahashi Toshiaki, Lai Xiaojing, Goto Koichi, Maneenil Kunlatida, Lee Ki Hyeong, Cobo Manuel, Valdiviezo Natalia, Evans Azura, Bolanos Ana, Huang Xiangning, Lai Rachel, Ramalingam Suresh S
Abstract excerpt
BACKGROUND: The LAURA study in unresectable stage III EGFR-mutated NSCLC without progression during/after chemoradiotherapy demonstrated significantly improved progression-free survival (PFS) with osimertinib versus placebo after definitive chemoradiotherapy. We report patient-reported outcomes (PROs) from LAURA. PATIENTS AND METHODS: Score changes from baseline (mixed model for repeated measures analysis) and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.